3[3]Covington E, Mendel DB, Escarpe PA, et al. Phenotypic and genotypic assay of influenza virus neuraminidase indicates a low incidence of viraldrug resistance during treatment with oseltamivir[J]. Ⅱ International Symposium on Influenza and other Respratory Virus,1999,11:10.
4[4]He G, Massarella J, Ward P. Summary of the clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite (Ro 64-0802)[J].Clin Pharmacokinet, 1999,37:471.
5[5]Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of oralneuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial (US oral neuraminidase study group)[J].JAMA, 2000,283:1 016.
6[6]Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial (neuraminidase inhibitor flu treatment investigator group)[J]. Lancet, 2000,355:1845.
7[7]Hayden FG, Atmar RL, Schilling M, et al. Safety and efficacy of a selective oral neuraminidase inhibitor (oseltamivir) to prevent influenza[J].N Engl J Med, 1999,341:1 336.
8[8]Silagy C, Campion K, Keeno O, et al. Randomized trial of efficacy andsafety of inhaled Zanamivir in treatment of influenza A and B virus infection. The MIST(Management of Influenza in the Southern Hemisphere Trialists) Study Group[J].Lancet,1998,352:1 877.
9[9]Fred YA, Douglas MF, Adrian DG, et al. Impact of Zanamivir treatment on productivity , health status and healthcare resource use in patients with influenza[J].Pharmacoeconomics, 2000,17:187.
10[10]Wutzler P, Vogel G. Neuraminidase inhibitors in the treatment of influenza A and B overview and case reports[J].Infection, 2000,5:261.
